TRAUMEEL® PRODUCT MONOGRAPH50

Study design 348 physicians completed surveys for patients in their care receiving

Traumeel® injection. 3,241 patients: 49.1% male, 50.5% female; mean age 47.5 years.

The most frequent complaint was forms of degenerative joint disease (primarily of the knee and hip), followed in descending order of frequency by myogelosis and sprains. Periathropatia humeroscapularis, epicondylitis and tendovaginitis were also treated.

Duration of symptoms was <1 week for 33.9% of patients, between 1 week and 1 month for 31.0%, and over 1 month for 33.7%.

Traumeel® was the only treatment for 19.2% of patients: 33.3% received non- medical therapy (e.g. application of heat or cold, massage), 14.9% received additional medical therapy (which could include other preparations of Traumeel®), and 31.1% combined additional medical and non medical therapy.

Frequency of application: daily 15.2%, 3 times a week 27.7%, twice weekly 40.1%, once weekly 13.6%.

Manner of application: intramuscular 24.0%, subcutaneous 17.8%, periarticular 14.6%, intra-articular 10.6%, peritendineal 7.0%, intravenous 4.3%, intracutaneous 2.8%, other 18.6%.

Duration of treatment: <1 week 15.9%, 1 week to 1 month 62.7%, 1 3 months 15.2%, 3 6 months 3.2%, >6 months 2.1%.

Outcome measures Physician-rated therapy outcome: very good, good, satisfactory,

unsuccessful, worsened.

Drug surveillance for Traumeel® injection

Zenner S, Metelmann H. Application possibilities of Traumeel® S injection solution: results of a multicentric drug monitoring trial conducted on 3,241 patients. Biol Ther. 1992;X(4):301 310.

STUDY DESIGN FORMULATION INDICATION(S) Multi-centric, drug monitoring trial.

Traumeel® injection. Various degenerative, traumatic and inflammatory affections.